SHAREHOLDER ALERT: Holzer & Holzer, LLC Reminds Investors of the October 28, 2024 Lead Plaintiff Deadline in Class Action Lawsuits Filed on Behalf of Verve Therapeutics, Inc. (VERV), Sage Therapeutics, Inc. (SAGE), and Outset Medical, Inc. (OM) Shareholders

ATLANTA, Oct. 24, 2024 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC reminds investors of the October 28, 2024 Lead Plaintiff deadline in the following class action lawsuits.

Verve Therapeutics, Inc.

A shareholder class action lawsuit has been filed against Verve Therapeutics, Inc. (“Verve Therapeutics” or “the Company”) (NASDAQ: VERV). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects, including allegations that: (1) Defendants did not fully disclose the circumstances under which the Heart-1 trial would be halted; and (2) Defendants overstated the potential benefits of its proprietary LNP delivery system.

If you bought shares of Verve Therapeutics between August 9, 2022 and April 1, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/verve-therapeutics/ to learn more.

Sage Therapeutics, Inc.

A shareholder class action lawsuit has been filed against Sage Therapeutics, Inc. (“Sage Therapeutics” or “the Company”) (NASDAQ: SAGE). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects, including allegations that: (i) zuranolone was less effective in treating major depressive disorder (“MDD”) than Defendants had led investors to believe; (ii) accordingly, the FDA was unlikely to approve the Zuranolone new drug application (“NDA”) for the treatment of MDD in its present form, and zuranolone’s clinical results for MDD, as well as its overall regulatory and commercial prospects, were overstated; (iii) SAGE-718 was less effective in treating mild cognitive impairment (“MCI”) due to Parkinson’s Disease (“PD”) than Defendants had led investors to believe; (iv) accordingly, SAGE-718’s clinical, regulatory, and commercial prospects as a treatment for MCI due to PD were overstated; (v) SAGE-324 was less effective in treating essential tremor (“ET”) than Defendants had led investors to believe; and (vi) accordingly, SAGE-324’s clinical, regulatory, and commercial prospects as a treatment for ET were overstated.

If you bought shares of Sage Therapeutics between April 12, 2021 and July 23, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/sage-therapeutics/ to learn more.

Outset Medical, Inc.

A shareholder class action lawsuit has been filed against Outset Medical, Inc. (“Outset Medical” or “the Company”) (NASDAQ: OM). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects, including allegations that: (1) the Tablo products were marketed for continuous renal replacement therapy, which is not one of the indications approved by the FDA; (2) as a result, Outset Medical was reasonably likely to submit an additional 510(k) application for the Tablo products; (3) there was a substantial risk that the Company would cease sales of the Tablo products pending FDA approval of additional indications; (4) Outset Medical lacked the sales team and process to execute on the ramp of Tablo sales; and (5) as a result of the foregoing, the Company’s revenue growth would be adversely impacted.

If you bought shares of Outset Medical between  September 15, 2020 and August 7, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/outset-medical/ to learn more.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, https://holzerlaw.com/, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.  

CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]

Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow